Oncomed Files IPO; Funds to Support CSC-Targeting Drugs
By Catherine Shaffer
Thursday, May 17, 2012
Oncomed Pharmaceuticals Inc. filed an initial public offering (IPO), hoping for about $115 million to support its antibody therapies targeted at cancer stem cells (CSCs).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.